Drugs / Plovamer acetate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01963611 | Oct 2013 → Mar 2015 | relapsing-remitting multiple sclerosis | EMD Serono | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plovamer acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01963611 ↗ |
| Known as | CO-14 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108712 ↗ |
| Known as | PI-2301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108712 ↗ |
| Known as | Pi-2301 acetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108712 ↗ |
| Modality | Small molecule | — CHEMBL2108712 ↗ |
| Target | HLA-DRB1 | “HLA class II histocompatibility antigen, DRB1-15 beta chain modulator” CHEMBL2108712 ↗ |